Drugs / AMB-05X
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06617858 | Dec 2024 → Feb 2028 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05349760 | Mar 2023 → Mar 2025 | idiopathic pulmonary fibrosis | AmMax Bio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05349643 | Jan 2023 → Jun 2024 | tenosynovial giant cell tumor | AmMax Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04938180 | Sep 2021 → Apr 2022 | tenosynovial giant cell tumor | AmMax Bio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04731675 | May 2021 → May 2022 | tenosynovial giant cell tumor, diffuse type | AmMax Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMB-05X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04938180 ↗ |
| Action | Inhibit | “AMB-05X is a fully human antibody antagonist” NCT04731675 ↗ |
| Modality | Monoclonal antibody | “AMB-05X drug substance is a human monoclonal antibody against the colony-stimulating factor 1 receptor (CSF1R).” NCT04731675 ↗ |
| Route | Other | “intra-articular injection of AMB-05X once every 2 weeks for 12 weeks” NCT04731675 ↗ |
| Target | CSF1R | “specific to the extracellular domain of human CSF1R” NCT04731675 ↗ |